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Background: Currently, 68Ga-labeled 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA)-peptides are the most
widely used class of 68Ga radiotracers for PET, although DOTA is not optimal for 68Ga complexation. More recently,
1,4,7-triazacyclononane-triacetic acid (NOTA) and particularly triazacyclononane-phosphinate (TRAP) chelators have
been shown to possess superior 68Ga binding ability. Here, we report on the efficiency, reproducibility, and
achievable specific activity for fully automated 68Ga labeling of DOTA-, NOTA-, and TRAP-peptide conjugates.
Findings: Compared to NOTA- and DOTA-peptides, achievable specific activity (AS) for TRAP-peptide is
approximately 10 and 20 times higher, respectively. AS values in the range of 5,000 GBq/μmol were routinely
obtained using 1 GBq of 68Ga, equivalent to 0.11 μg of cold mass for a 185-MBq patient dose of a 3-kDa conjugate.
The TRAP-peptide could be 68Ga-labeled with excellent reproducibility and> 95% radiochemical yield for precursor
amounts as low as 1 nmol.
Conclusions: High 68Ga labeling efficiency of TRAP-peptides could facilitate realization of kit labeling procedures.
The good reproducibility of the automated synthesis is of relevance for GMP production, and the possibility to
provide very high specific activities offers a high degree of safety in first clinical trials, due to reduction of cold mass
content in tracer formulations.
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Background
With the commercial availability of 68Ge/68Ga generators,
cyclotron-independent on-site production of tracers for
positron-emission tomography (PET) has become widely
feasible [1,2]. Thus, in the near future, a ubiquitous imple-
mentation of PET and PET/CT even in regions with less
well-developed infrastructure can be expected, similar to
the global story of success of 99mTc-based scintigraphy
which started half a century ago with the introduction of
99Mo/99mTc generators [1,3]. In the long run, a partial
substitution of single photon emission computed tomog-
raphy (SPECT) by PET (and SPECT/CT by PET/CT, re-
spectively) appears to be a realistic scenario in view of the
advantages of PET, such as superior spatial resolution and* Correspondence: johannes.notni@tum.de
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provided the original work is properly cited.sensitivity. Besides, in contrast to reactor-produced 99Mo,
68Ge is cyclotron-produced. This can be considered ad-
vantageous with regard to the recent insufficiency of glo-
bal reactor capacity for reliable 99Mo supply [4], and
independence of 68Ga-PET from nuclear reactors might
positively influence the bias of its public perception.
Generally, 68Ga labeling is done by complexation of
the 68Ga3+ ion. For this purpose, dedicated chelators
usually have to be introduced into precursor molecules
by bioconjugation, wherein they readily determine the
labeling chemistry. To facilitate global implementation
of 68Ga-PET, production of 68Ga radiopharmaceuticals
must be simple, robust, and reliable; this demands highly
efficient labeling chemistry and, therefore, highly effi-
cient chelators. Recently, we have shown that the bifunc-
tional triazacyclononane-phosphinate (TRAP) ligand [5-8]
possesses markedly improved 68Ga labeling properties [6].
This applies also to TRAP-based peptide conjugates, theicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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this study.Methods
TRAP(RGD)3 was prepared as described before [6].
NODAGA-cyclo(RGDyK) (‘NODAGA-RGD’) was pur-
chased from ABX GmbH (Radeberg, Germany). DOTATOC
was obtained from Bachem (Bubendorf, Switzerland).
Fully automated 68Ga labeling was performed using un-
purified eluate fractions of a 68Ge/68Ga generator with
SnO2 matrix (iThemba LABS, Somerset West, South
Africa), as described previously [6,9] (5 min reaction at
95°C, pH adjusted with HEPES, pH 3.2 for DOTATOC
and NODAGA-RGD, pH 2 for TRAP(RGD)3, purifica-
tion using C8 SPE cartridge). Radiochemical yield was
calculated from decay-corrected product activity in
relation to the sum of significant decay-corrected re-
sidual activities contained elsewhere, that is, in reactionFigure 1 Structures of peptide conjugates used in this study. The com
TRAP(RGD)3, NODAGA-RGD, and DOTATOC, respectively, are highlighted invial, SPE cartridge, and non-product cartridge purging
liquids.
Calculation of specific activities
Product activities (AP) were measured after the end of
preparation (approximately 15 min after the start of syn-
theses) and decay corrected to a typical injection time,
30 min after the start of synthesis (AP,30). In order to be
able to calculate corresponding specific activity values
that are representative for the respective precursor
amounts and independent from small deviations in the
starting activity A0 (in our experiments, ranging from
800 to 1,050 MBq, depending on the regeneration state
of the 68Ga generator), product activities were normal-
ized to a representative starting activity AN= 1 GBq,
according to AP;30;N ¼ AP;30 ANA0
 
. Specific activity (AS)
values were calculated by the division of AP,30,N by the
precursor amount used. It is assumed that all precursorplexation sites of TRAP, NOTA, and DOTA-monoamide, featured in
blue color.
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from the cartridge, and thus transferred into the formula-
tion. This means that both retention and elution efficiency
are considered 100%, both of which can be somewhat
lower in practice. As a result, all given AS represent the
lower bounds and will never overestimate actual values.
Results and discussion
Although previous comparative studies focusing on the
basic chelator structures TRAP, 1,4,7-triazacyclononane-
triacetic acid (NOTA), and 1,4,7,10-tetraazacyclodode-
cane-tetraacetic acid (DOTA) already proved superior
Ga3+ complexation/68Ga labeling properties of TRAP
[6,7], these data are not sufficient to quantify the behavior
of respective peptide conjugates, for two reasons: Firstly,
functionalization of chelators with peptides, resulting in
conjugates with a multiple of the molecular weight of
the neat chelators, is definitely prone to change overallFigure 2 Radiochemical yields and corresponding calculated minimal
lines, %, mean± SD, n≥ 4) and corresponding calculated minimal AS (dashe
injection (30 min after the start of synthesis) as functions of precursor amo
and DOTATOC (D). AS for TRAP(RGD)3 concentrations> 1 nmol are not shocomplexation properties with potentially unpredictable
outcome. Secondly, the chelating moiety in compounds
commonly dubbed ‘DOTA-peptides’ is actually not
DOTA, but DOTA-monoamide (see Figure 1), which
exhibits different Ga3+ complexation behavior [10]. In
contrast, for TRAP and the bifunctional NOTA-derivative
NODAGA, the structure of the chelating site is not
affected by conjugation. To assess the impact of these
effects, representative peptide conjugates (TRAP(RGD)3
[6] and the commercially available ‘NOTA’- and ‘DOTA’-
peptides NODAGA-RGD and DOTATOC, respectively,
see Figure 1) were labeled under similar conditions using
our standard automated procedure [6,9].
Figure 2 shows that TRAP(RGD)3 allows to use much
lower precursor concentrations for labeling than
required for NODAGA-RGD and particularly DOTA
TOC, which is why 68Ga-TRAP(RGD)3 can be prepared
with much higher AS (see also Table 1). Using 0.1 nmolAS of radiopharmaceutical formulations. Radiochemical yields (solid
d lines, GBq/μmol, mean± SD) of the formulations at typical time of
unt for automated 68Ga labeling of TRAP(RGD)3 (T), NODAGA-RGD (N),
wn for clarity of presentation.
Table 1 Radiochemical yields of automated 68Ga labeling,









0.017 27.9 ± 16.0 12059± 6922
0.04 42.9 ± 14.0 7889 ± 2567
0.1 65.8 ± 5.6 4848 ± 414
0.33 90.0 ± 2.7 2006 ± 61
1 95.2 ± 1.7 701± 12
10 97.8 ± 0.5 73 ± 0.4
68Ga-DOTATOC
0.6 34.4 ± 21.3 422± 261
2.2 63.7 ± 13.5 213± 45
7 82.8 ± 8.7 87 ± 9
14 88.0 ± 2.1 46 ± 1.1
68Ga-NODAGA-RGD
0.22 31.7 ± 28.4 1059 ± 951
0.4 51.9 ± 22.8 954± 419
1 74.1 ± 15.2 545± 112
2 85.0 ± 7.4 313± 28
6 94.7 ± 1.1 116± 1.3
20.5 93.7 ± 1.9 34 ± 0.7
At typical time of injection (30 min after start of synthesis), values given as
mean ± SD.
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with a satisfying decay-corrected yield of 66 ± 6%. The
use of even lower amounts of TRAP(RGD)3 (17 pmol)
frequently resulted in preparations with extremely high
AS of >10,000 GBq/μmol, although not reliably reprodu-
cible. The highest AS value observed during these experi-
ments was 14,900 GBq/μmol (actual value, not
normalized to starting activity), which is approximately
1/7 of the theoretically possible maximum value, that of
carrier-free 68Ga. Although such high specific activities
are not usually needed for clinical applications, we
nevertheless, deem this feature of high practical value
for the following reasons:
1. A hypothetical patient dose of 185 MBq (5 mCi) of a
5,000-GBq/μmol preparation contains only 37 pmol
of peptide; for a compound like TRAP(RGD)3 with a
molecular weight of 3 kDa, this calculates to a total
of 0.11 μg of cold mass, or less than 2 ng/kg body
weight for an average patient. Such tiny amounts are
extremely unlikely to cause any pharmacological
effects. Therefore, TRAP could facilitate the use of
such biomolecules for imaging that possess very high
pharmacological potential, and 68Ga-labeled TRAPconjugates could generally offer high safety when
tested in first clinical trials.
2. As a 15-MBq dose of said preparation is equivalent to
3 pmol or 9 ng of our exemplary 3-kDa peptide, it can
always directly be used for evaluation studies in
rodents without having to separate off unlabeled
precursor or, unfavorably, reduce the administered
dose. High receptor occupancy or even saturation
effects, which otherwise are frequently encountered in
small animal imaging due to the necessity of applying
much higher activity doses per kilogram body weight
than in humans, can be practically ruled out.
3. Several studies have outlined that the amount of co-
injected cold mass can have a significant influence on
biodistribution and imaging results [11-14]. In clinical
routine, it is therefore highly recommended to utilize
radiopharmaceutical formulations with constant,
optimized specific activity (i.e., well-defined cold mass
content). Such productions could be done most
conveniently and reliably by adding the desired
amount of active compound to a pre-conditioned vial
containing a fixed amount of cold standard. This
approach, however, requires radiolabeled tracers with
very high specific activity in order not to change the
overall contained amount of cold mass significantly.
68Ga-labeled TRAP conjugates appear ideally suited
for this purpose.
Furthermore, regarding Figure 2, one notices that vari-
ation of radiochemical yields, reflected by the size of
error bars, is the larger the lower precursor amounts
are. This is because the generator eluate usually contains
traces of ionic contaminants, such as Zn2+, Sn4+, Al3+,
and Fe3+, the concentration of which in the individual
eluates is varying. These can compete with 68Ga3+ at the
chelating site of the precursor, which is naturally the
more impacting on labeling yield the lower the stoichio-
metric excess of precursor over 68Ga3+ ion is. The error
bars in Figure 2 show that except for precursor amounts
exceeding 20 nmol, use of a TRAP peptide will result in
a more reliable radiosynthesis, being less prone to be
perturbed by variation of other parameters (reaction pH,
eluate volume, trace metal contaminations, etc.). Differ-
ences in radiochemical yield and reproducibility are very
pronounced for peptide amounts in the range of 1 to
10 nmol (e.g., equivalent to 1.4 to 14 μg of DOTATOC)
which are frequently used in routine 68Ga labeling pro-
cedures; near-quantitative yields and excellent reprodu-
cibility can be expected here for a TRAP peptide. This is
of high relevance for routine GMP tracer production,
where reproducibility and robustness of procedures is
crucial. In addition, we assume that due to higher label-
ing efficiency, realization of kit labeling procedures will
be much simpler using TRAP conjugates, which we
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of global implementation of 68Ga-PET. Finally, the re-
cent introduction of NOPO, a TRAP variety designed
specifically for monoconjugation, expands the portfolio
of P-functionalized triazacyclononane-triphosphinate
chelators, thus offering even more synthetic possibilities
for development of 68Ga tracers [15].
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